Insmed, Inc. (INSM) — Analysis Summary
Insmed, Inc. (INSM) has a market cap of $26.77B with year-over-year revenue growth of +66.7%. Net margin stands at -210.5%. The stock trades at a P/E ratio of -30.6.
Key Takeaways
- Revenue changed +66.7% year-over-year
- Net margin of -210.5%
- P/E ratio of -30.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, INSM posted revenue growth of +66.7% and trades at a P/E of -30.6.
Insmed, Inc. (INSM)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -10.3x — earnings do not cover interest payments
Operating margin at -73.9% — severe operating losses
Net margin at -76.9% — significant losses
The latest filing shows negative free cash flow.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
1,664
Headquarters
BRIDGEWATER, NJ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.